Tag: Cancer: Lymphoma
FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
                    Textured implants linked to cases of anaplastic large cell lymphoma                
            Chemo-Radiation Combo Tied to Higher Survival in Peds Hodgkin
                    Five-year overall survival higher in patients who receive combined tx than those treated with chemo alone                
            Childhood Hodgkin Lymphoma Survivors at Risk for Later Cancers
                    Survivors have 14-fold increased risk for developing a solid subsequent malignant neoplasm                
            American Society of Hematology, Dec. 1-4
                    
The 60th American Society of Hematology Annual Meeting and Exposition  The annual meeting of the American Society of Hematology was held from Dec....                
            ASH: A+CHP Bests CHOP for Peripheral T-Cell Lymphoma
                    Median progression-free survival improved with A+CHP vs CHOP; similar incidence of adverse events                
            ASH: High Response to Tx After Checkpoint Blockade in NHL, HL
                    Immunotherapy boosts later therapy for relapsed, refractory non-Hodgkin, Hodgkin lymphoma                
            FDA Approves First Biosimilar to Non-Hodgkin’s Lymphoma Drug
                    Truxima approved to treat adults with CD20-positive, B-cell non-Hodgkin's lymphoma                
            FDA Approves First-Line Tx for Peripheral T-Cell Lymphoma
                    Adcetris approved in combination with chemo to treat systemic anaplastic large cell lymphoma                
            Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL
                    Duvelisib extended progression-free survival to 13.3 months versus 9.9 months for ofatumumab                
            Rituximab + Lenalidomide Effective in Follicular Lymphoma
                    Response rate, progression-free survival comparable to those seen with rituximab-chemotherapy                
             
                